CM Energy plays a role in the cultivation and expansion of emerging industries during the 14th Five-Year Plan period of China Merchants Group

The China Merchants Group's "14th Five-Year Plan" High-Quality Development Achievements Exhibition recently opened, systematically reviewing and showcasing the group's achievements in high-quality development during the "14th Five-Year Plan" period. This issue introduces the Group's new breakthroughs in cultivating and expanding emerging industries.

During the "14th Five-Year Plan" period, the Group fully leveraged its comprehensive advantages in "technology-industry-finance" to develop new-quality productivity, accelerate the cultivation and expansion of emerging industries, and strive to create a "new growth pole" for high-quality development. It has initially formed emerging industry clusters in high-end equipment manufacturing, inspection and testing certification, bio-manufacturing, and biomedicine.

The Group's revenue from emerging industries has grown rapidly, with a compound annual growth rate of 18.4%, accounting for 11.6% of the Group's total revenue. If the revenue of major invested enterprises is included, the proportion reaches 15.5%.

Strategic Investment in Cathay Biotech

In 2025, the Group will complete its strategic investment in Cathay Biotech, accelerating the industrialization and commercialization process through technological innovation and industrial synergy, creating a new engine for the bio-economy and a model of state-owned enterprise practice.

The image shows the Cathay (Shanxi) Biomaterials Industrial Cluster.

The image shows the Cathay (Wusu) plant: the world's first industrial-scale bio-based pentanediamine and bio-based polyamide plant.

The image shows the Cathay (Jinxiang) plant: the world's first bio-based polymerization-grade long-chain dicarboxylic acid production base.

The image shows the Hefei production base (under construction): a globally leading industrial base for bio-based composite materials and application development.

Caesar Bio is a STAR Market-listed company that utilizes biomanufacturing technology based on synthetic biology and other disciplines to engage in the R&D, production, and sales of bio-based new materials. It possesses several large-scale industrialized biotechnologies, including bio-based long-chain dicarboxylic acids, bio-based pentanediamine, bio-based polyamide, and composite materials.

Restructuring and Controlling the Controlling Company, Humanwell Healthcare

In 2025, the company will restructure and control Humanwell Healthcare, leveraging its comprehensive R&D and sales system to build a life science and technology industrial platform. Humanwell Healthcare is a leading domestic enterprise in anesthetic drugs, one of China's top 20 pharmaceutical industrial enterprises, a national enterprise technology center, and a national technology innovation demonstration enterprise. It has established a leading or dominant position in several sub-sectors in China, including nervous system drugs, steroid hormones, and Uyghur medicine.

Yichang Humanwell Pharmaceutical: The largest designated R&D and production base for anesthetic drugs in China, and the world's most comprehensive commercial manufacturer of fentanyl products.

Gedian Humanwell Pharmaceutical: Holds the number one global market share in progesterone raw materials, and leads in market share for raw materials such as finasteride and budesonide.

Xinjiang Uyghur Pharmaceutical: A leading enterprise in China's Uyghur medicine industry, a inheritor of Uyghur medicine culture, and a pioneer in the industrialization of Uyghur medicine.

Cultivating and nurturing emerging industry projects:

China Merchants Venture Capital and New Industry Fund comprehensively cover three major areas: digital technology, life sciences, and green technology, focusing on sub-sectors such as embodied intelligence, synthetic biology, green energy, and biomedicine, with a cumulative investment exceeding 3 billion yuan.

China Merchants Shipbuilding effectively controls CM Energy

CM Energy continues to expand its green technology capabilities in areas such as marine green fuel production and supply, hydrogen-based energy and marine equipment manufacturing, and electronic control and deep-sea technology.

Hydrogen-based Energy

Marine Machinery Equipment

Intelligent Electronic Control

China Merchants Innovation Technology increases capital and consolidates Tianjin Institute of Pharmaceutical Research

Completed the capital increase and consolidation by the end of 2024, strengthening strategic management and continuously building a national-level scientific research and development platform for "synthetic biology technology origin" and "drug drugability evaluation and system transformation".

Integrating resources to accelerate the layout of the testing and inspection industry

China Merchants Testing acquired and restructured China Merchants New Testing, creating the first successful example of provincial-level integrated transformation of national quality infrastructure into an enterprise and central-local cooperation reform in China; and built the East China (Hefei) Testing Base.

The image shows the unveiling ceremony of China Merchants Xinjiang Testing Technology Research Institute Co., Ltd. in October 2024.

The image shows the China Merchants Testing East China (Hefei) Testing Base.

Jointly Building a Bio-based Composite Materials Production and R&D Platform

China Merchants Innovation Technology, together with Cathay Biotech and the Hefei Municipal Government, jointly built a bio-based composite materials production and R&D platform to promote the application scenarios, technological breakthroughs, and industrial upgrading of the bio-manufacturing industry.

The image shows the signing of a strategic cooperation agreement by the Hefei Municipal Government, China Merchants Innovation Technology, and Cathay Biotech.

The image shows the rendering of the China Merchants Cathay Hefei Composite Materials Project.

Cultivating and Incubating Biomedical Innovation Platforms and Products

Leveraging its industrial and financial advantages, the Group has facilitated investments from multiple institutions, including Haihe Fund and the Macau University of Science and Technology Foundation, in Hechuang Biotech. Through its national-level science and technology business incubator, it incubated the "Cell Technology Innovation Platform and Products" project, which won first prize in the 4th Central Enterprises Shining Star Innovation and Creativity Competition.

Hechuang Biotechnology's Innovations in Systems and Mechanisms

◆ Building a technology platform for cell product R&D, production, and quality control

◆ Establishing a complete cell industry chain operation system

◆ Gathering a team for scientific and technological innovation and transformation

◆ Participating in the formulation of national, industry, and local standards

◆ Fully utilizing social capital and diversified resources through market-based financing